Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Sanofi Stories

2013-08-09 08:23:48

Editor Note: For more information about this release, please scroll to bottom. LONDON, August 9, 2013 /PRNewswire/ -- On Thursday August 8, 2013, shares in healthcare companies ended on a higher note, tracking gains in the broader market. The major movers in the healthcare sector on Thursday included Vivus Inc. (NASDAQ: VVUS), Sanofi (NYSE: SNY), DENTSPLY International Inc. (NASDAQ: XRAY), and Acura Pharmaceuticals Inc. (NASDAQ: ACUR). AAAResearchReports.com tracked VVUS, SNY,...

2013-08-01 08:32:55

PARIS, Aug. 1, 2013 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q2 2013 Change (reported) Change (CER) H1 2013 Change (reported) Change (CER) ------- ---------------- ----------- ------- ---------------- ----------- Net sales EUR8,003m...

2013-07-31 20:21:31

- Treats Seasonal and Year-round Nasal Allergy Symptoms in Adults and Children - PARIS, July 31, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration's (FDA) Nonprescription Drugs Advisory Committee (NDAC) voted 10 to 6, with 2 abstentions, recommending approval of Nasacort(®) AQ Nasal Spray (triamcinolone acetonide) for over-the-counter use in the U.S. (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO)...

2013-07-19 08:26:57

LIBOURNE, France, July 19, 2013 /PRNewswire/ -- Ceva Sante Animale S.A. today signed a definitive agreement to acquire a controlling stake in Sichuan Hengtong's animal health subsidiary in China. E. J. McKay acted as the exclusive financial advisor to CEVA. The transaction will allow CEVA to significantly increase its business scope in China, especially in the chemical drug segment for animal health. Representatives from the Chinese Embassy in Paris and the French Ministry of Foreign...

2013-07-15 16:23:30

NEW YORK, July 15, 2013 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the discovery and development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today that James Hendrix, Ph.D., has been appointed Senior Director of Chemistry of the company. Dr. Hendrix has more than 20 years of pharmaceutical research experience, predominantly in the area of neuroscience research, including AD. His focus...

2013-07-04 08:21:36

NEW YORK, July 4, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Wall Street Reports announced new research reports highlighting Novo Nordisk A/S (NYSE: NVO), Novartis AG (NYSE: NVS), GlaxoSmithKline plc (NYSE: GSK), Sanofi (NYSE: SNY), and Neurocrine Biosciences Inc. (NASDAQ: NBIX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings -...

2013-06-27 23:52:49

Rockville, MD | 6/26/2013 | PRWeb – MarketResearch.com announces the addition of a new market research report in Pharmaceuticals to their product offering: New Oral Anticoagulants Markets http://www.marketresearch.com/land/product.asp?productid=7458266&progid=85535 (PRWEB) June 26, 2013 New Oral Anticoagulants Markets TriMarkPublications.com cites in its newly published “New Oral Anticoagulants Markets” report that the global anticoagulants market will spike to over $24 billion...

2013-06-26 08:30:33

OXFORD, England, June 26, 2013 /PRNewswire/ -- Oxford BioTherapeutics (OBT), a global biotechnology company developing first-in-class, antibody-based cancer medicines to fulfil unmet patient needs, today announces the appointment of Bryan G. Morton as the Company's new Non-executive Chairman. Bryan Morton has over 30 years experience as a successful entrepreneur and senior manager in the pharmaceutical industry. Morton was previously CEO of EUSA Pharma, a global...

2013-06-22 16:20:18

BRIDGEWATER, N.J. and BOSTON, June 22, 2013 /PRNewswire/ -- Sanofi US collaborated with Joslin Diabetes Center on a successful, multicultural outreach pilot that was overseen and funded by Sanofi US with Joslin as its partner in providing clinical and behavioral educational materials and training based on their award-winning On the Road diabetes program. The pilot, which was implemented in four ethnically diverse cities across the United States, demonstrated a significant reduction in...

2013-06-22 12:21:35

- EDITION I demonstrated similar blood sugar control with fewer night-time low blood sugar events compared to Lantus® - PARIS, June 22, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the first Phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus(® )(insulin glargine [rDNA origin] injection). The company also announced topline...